Lots that continues to go up annually.
Modern Healthcare: AHRQ Releases Stats On State Of Primary-Care Workforce Despite serving as the ‘foundational element’ of the U.S. Healthcare system, the country’s primary-treatment network is experiencing ‘diminishing economic margins, and raising workforce attrition compounded by diminishing recruitment of fresh physicians, nurses and physician assistants into primary care,’ according to the U.S. Agency for Healthcare Study and Quality. AHRQ’s Center for Principal Care, Prevention and Clinical Partnership will end up being issuing a ‘Information and Stats Series’ on primary-care topics made to inform healthcare policy and decisionmakers on major care’s workforce, capability and development needs . Related StoriesUsing integrated molecular pathology to control incidental pancreatic cysts: an interview with Dr Ananya DasGenetic carrier screening: an interview with Don Hardison, CEO of Good Begin GeneticsApplying a high restaurant model to health care communications: an interview with Brandi Robinson, SanofiAlso in the news, Medscape reports on a diagnostic coding program change which will present a variety of new problems to doctors – Medscape: Three Issues That ICD-10 Brings to Doctors On a go-forward basis, because of the improved specificity around ICD-10 [diagnostic coding system], there is the increased chance that improper coding will probably negatively affect reimbursements a lot more so than today due to that increased specificity.The protection profile was similar to previous studies no unexpected safety signals were reported for venetoclax. Related StoriesPotential new medication target for acute myeloid leukemiaProtein-coding gene defined as tumor suppressor for severe myeloid leukemiaAnalysis of high-throughput sequencing data reveals fresh genes linked to chronic lymphocytic leukemia’The outcomes from this research demonstrate the medical activity of venetoclax in sufferers with relapsed/refractory CLL who have 17p deletion, a patient population that has historically been difficult to treat,’ stated Michael Severino, M.D., executive vice president of analysis and chief and development scientific officer, AbbVie.